Revance Therapeutics Inc (NAS:RVNC)
$ 2.88 -0.01 (-0.35%) Market Cap: 300.81 Mil Enterprise Value: 503.17 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc Investor Day Transcript

Sep 19, 2023 / 01:30PM GMT
Release Date Price: $13.81 (-17.31%)
Operator

Please welcome Chief Executive Officer, Mark Foley.

Mark J. Foley
Revance Therapeutics, Inc. - CEO & Director

Great. Thanks, everyone, and welcome to our Investor Day. This is the first time we've hosted one of these Investor Days in 5 years. So we thought it was particularly timely for us to do it given the recent approval of DAXXIFY in Aesthetics and more recently in Therapeutics and where we are in our commercial journey. So we're really excited today to share with you where we are in the journey, why we have conviction and confidence in both our strategy and opportunity for success that we have going forward. Before I jump into the agenda and everything, I'd also like to welcome Valerie Toppan or -- the CEO and Founder of Teoxane and we're very fortunate to be in partnership with Valerie and the RHA line of fillers. So thanks, Valerie for making the trip from Europe over here and for being such a supportive shareholder as well.

In terms of the program that we're going to cover, we'll start out with the overall aesthetics market. We have an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot